AbbVie Achieves Phase 1 Milestone for ABBV-295 Amylin Analog Supporting Monthly Dosing Intervals

Monthly dosing intervals for a subcutaneous injectable obesity therapy carry formulation and fill-finish implications that CDMOs and internal manufacturing teams should begin mapping now: AbbVie presented detailed Phase 1 MAD data for ABBV-295 at the EASD 2026 Annual Meeting in Milan, confirming a mean half-life of 10.7 to 12.3 days and dose-proportional plasma exposure that supports once-weekly, every-other-week, and monthly regimens.

The dataset draws from 60 participants in Parts 2B/2C of the MAD study, 45 on active drug, 15 on placebo, dosed at 4, 6, or 14 mg once weekly, 14 mg every other week, or 8 mg monthly over 12 to 13 weeks. Median Tmax ranged from 24.0 to 48.1 hours. Meaningful, dose-dependent body weight reduction was observed across all regimens, with no serious treatment-emergent adverse events reported.

The GI tolerability profile warrants attention for clinical supply planning. Nausea occurred in 33.3% of ABBV-295 participants versus 20.0% on placebo; diarrhea in 20.0% versus 0.0%. Critically, 92% of participants who experienced a GI adverse event reported only mild severity as the highest grade, and discontinuations due to GI events were low at 4.4% in the active arm. GI events clustered within the first six weeks, a pattern relevant to dose-escalation protocol design in Phase 2.

ABBV-295 operates through the amylin pathway, mechanistically distinct from GLP-1 and GIP receptor agonists. That distinction has direct manufacturing consequences: an extended half-life supporting monthly subcutaneous dosing implies different concentration requirements, container-closure compatibility considerations, and potentially lower annual injection volumes per patient compared with weekly GLP-1 injectables, each a variable that affects fill-finish line configuration and batch sizing assumptions.

With Phase 2 advancement confirmed, CDMOs and internal sterile manufacturing units supporting AbbVie's pipeline should expect process development work to intensify around subcutaneous formulation stability at the concentrations required for monthly delivery, alongside the analytical method development needed to characterize a long-acting peptide analog under ICH Q10-aligned quality systems.

The Phase 2 program's design, including dose selection, patient population BMI thresholds, and dosing interval arms, will be the next measurable checkpoint for manufacturing and regulatory teams tracking ABBV-295's development trajectory.

Source: AbbVie News Center via PR Newswire, September 30, 2026. Data presented as a short oral presentation at EASD 2026 Annual Meeting, Milan, Italy, September 28 – October 2, 2026.